Dov Bergwerk, Interim Chief Legal Officer of Teva Pharmaceutical Industries Ltd., filed a Form 4 on November 6, 2026, disclosing the exercise of two tranches of stock options and the same-day sale of the resulting ordinary shares on November 4, 2026.

Key Highlights

  • First option exercise: Bergwerk exercised 17,505 stock options at an exercise price of $34.70, acquiring 17,505 ordinary shares on November 4, 2026.
  • Second option exercise: Bergwerk exercised 8,755 stock options at an exercise price of $28.98, acquiring 8,755 ordinary shares on the same date.
  • Shares sold: Both tranches of acquired shares, totaling 26,260 ordinary shares, were sold at $41.72 per share on November 4, 2026.
  • Remaining beneficial ownership: Following all reported transactions, Bergwerk directly held 11,943 ordinary shares.
  • Option grant history: The $34.70 options were granted March 3, 2017; the $28.98 options were granted May 24, 2017, with both fully vested by 2021 according to the filing.

Bergwerk's November 4 Option Exercises and Share Sales at Teva

According to the filing, Dov Bergwerk, identified as Interim Chief Legal Officer of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), reported two stock option exercises and corresponding share sales on November 4, 2026. In the first transaction, Bergwerk exercised 17,505 stock options at a conversion price of $34.70, acquiring 17,505 ordinary shares. Those shares were then sold the same day at $41.72 per share. Following this pair of transactions, Bergwerk's direct beneficial ownership stood at 11,943 ordinary shares.

In the second transaction reported on the same date, Bergwerk exercised 8,755 stock options at a conversion price of $28.98, acquiring 8,755 ordinary shares, which were also sold at $41.72 per share. The filing notes that after both sales, Bergwerk's direct holdings remained at 11,943 ordinary shares. The filing records a price of $0 for each option exercise in Table II, consistent with the standard reporting of the derivative security's price at exercise.

The filing's explanations of responses state that the $34.70 options were granted on March 3, 2017, with 4,376 shares having vested on each of March 3, 2018, March 3, 2019, and March 3, 2020, and 4,377 having vested on March 3, 2021. The $28.98 options were granted on May 24, 2017, with 2,188 shares vesting on each of May 24, 2018, May 24, 2019, and May 24, 2020, and 2,191 vesting on May 24, 2021. Following the reported transactions, neither option tranche carries any remaining derivative securities, according to the filing.

What Was Disclosed

The Form 4 discloses two stock option exercises and same-day sales of ordinary shares by Teva's Interim Chief Legal Officer, Dov Bergwerk, on November 4, 2026, resulting in direct beneficial ownership of 11,943 ordinary shares after the transactions.